Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab selectively depletes effector memory T cells and promotes relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psori
CAS Number:
[288392-69-8]
Target:
MEDI-507
* VAT and and shipping costs not included. Errors and price changes excepted